rosiglitazone has been researched along with nephrin in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 4 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| den Ouden, K; Goldschmeding, R; Joles, JA; Nguyen, TQ; Verhaar, MC; Westerweel, PE | 1 |
| Burt, D; Camussi, G; Gruden, G; Miceli, I; Perin, PC; Tarabra, E | 1 |
| Chan, LY; Cheng, AS; Lai, KN; Lan, HY; Leung, JC; Tang, SC | 1 |
| Barone, F; Bilous, R; Buckingham, R; Dessapt, C; Gnudi, L; Gruden, G; Hayward, A; Hiroshi, K; Setti, G; Viberti, G; White, K | 1 |
| Chodavarapu, H; Elased, KM; Grobe, N; Madhu, M; Salem, ES; Somineni, HK | 1 |
5 other study(ies) available for rosiglitazone and nephrin
| Article | Year |
|---|---|
Amelioration of anti-Thy1-glomerulonephritis by PPAR-gamma agonism without increase of endothelial progenitor cell homing.
Topics: Aneurysm; Animals; Blood Pressure; Bone Marrow Transplantation; Cell Movement; Disease Models, Animal; Endothelial Cells; Extracellular Matrix; Fibronectins; Gene Expression; Glomerulonephritis, Membranous; Hypoglycemic Agents; Isoantibodies; Kidney Cortex; Kidney Glomerulus; Male; Membrane Proteins; Plasminogen Activator Inhibitor 1; PPAR gamma; Proteinuria; Rats; Rats, Inbred BN; Rosiglitazone; Stem Cells; Thiazolidinediones; Transforming Growth Factor beta; Urea | 2008 |
Stretch reduces nephrin expression via an angiotensin II-AT(1)-dependent mechanism in human podocytes: effect of rosiglitazone.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Apoptosis; Cell Proliferation; Cells, Cultured; Diabetic Nephropathies; Down-Regulation; Humans; Membrane Proteins; Podocytes; PPAR gamma; Receptor, Angiotensin, Type 1; RNA, Messenger; Rosiglitazone; Stress, Mechanical; Thiazolidinediones; Up-Regulation | 2010 |
Renoprotection by rosiglitazone in accelerated type 2 diabetic nephropathy: Role of STAT1 inhibition and nephrin restoration.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Down-Regulation; Kidney; Kidney Glomerulus; Male; Membrane Proteins; Mice; Mice, Inbred C57BL; Nephrectomy; Protective Agents; Rosiglitazone; STAT1 Transcription Factor; Thiazolidinediones | 2010 |
Peroxisome proliferator-activated receptor-γ agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes.
Topics: Albuminuria; Animals; Cells, Cultured; Chemokine CCL2; Diabetes Mellitus, Experimental; Diabetic Nephropathies; Hypoglycemic Agents; Kidney; Macrophages; Male; Membrane Proteins; PPAR gamma; Rats; Rats, Sprague-Dawley; Rosiglitazone; Thiazolidinediones | 2010 |
Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion.
Topics: ADAM Proteins; ADAM17 Protein; Albuminuria; Angiotensin-Converting Enzyme 2; Animals; Blood Glucose; Diabetes Mellitus, Type 2; Disease Models, Animal; Glucagon; Glucose Tolerance Test; Glycosuria; Hyperglycemia; Hypoglycemic Agents; Kidney Diseases; Male; Membrane Proteins; Mice; Peptidyl-Dipeptidase A; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinase-3; Triglycerides | 2013 |